Biotech Lobbying Threatens Major Savings in Medicare Drug Pricing Pilot

By Ed Silverman · STAT News · 2026-08-05

According to STAT News, industry pressure to exempt orphan drugs from the GUARD pricing initiative could significantly undermine the program's financial impact. While the Trump administration aims to align domestic retail drug costs with international benchmarks, Harvard research

According to STAT News, industry pressure to exempt orphan drugs from the GUARD pricing initiative could significantly undermine the program's financial impact. While the Trump administration aims to align domestic retail drug costs with international benchmarks, Harvard research